The “-OMICS” facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers

Douglas Donnelly; Phyu P. Aung; George Jour

doi:10.1016/j.semcancer.2019.06.014

The “-OMICS” facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers

Douglas Donnelly, Phyu P. Aung, George Jour

Pathology

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

In the recent decade, cutting edge molecular and proteomic analysis platforms revolutionized biomarkers discovery in cancers. Melanoma is the prototype with over 51,100 biomarkers discovered and investigated thus far. These biomarkers include tissue based tumor cell and tumor microenvironment biomarkers and circulating biomarkers including tumor DNA (cf-DNA), mir-RNA, proteins and metabolites. These biomarkers provide invaluable information for diagnosis, prognosis and play an important role in prediction of treatment response. In this review, we summarize the most recent discoveries in each of these biomarker categories. We will discuss the challenges in their implementation and standardization and conclude with some perspectives in melanoma biomarker research.

Original language	English (US)
Pages (from-to)	165-174
Number of pages	10
Journal	Seminars in cancer biology
Volume	59
DOIs	https://doi.org/10.1016/j.semcancer.2019.06.014
State	Published - Dec 2019

Keywords

Epigenetic biomarker
Melanoma
Metabolomics
Proteomics
Serum biomarker
mir-RNA

ASJC Scopus subject areas

Cancer Research

Access to Document

10.1016/j.semcancer.2019.06.014

Cite this

@article{8e8091c58eb1453cafbc7b657e6736f9,

title = "The “-OMICS” facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers",

abstract = "In the recent decade, cutting edge molecular and proteomic analysis platforms revolutionized biomarkers discovery in cancers. Melanoma is the prototype with over 51,100 biomarkers discovered and investigated thus far. These biomarkers include tissue based tumor cell and tumor microenvironment biomarkers and circulating biomarkers including tumor DNA (cf-DNA), mir-RNA, proteins and metabolites. These biomarkers provide invaluable information for diagnosis, prognosis and play an important role in prediction of treatment response. In this review, we summarize the most recent discoveries in each of these biomarker categories. We will discuss the challenges in their implementation and standardization and conclude with some perspectives in melanoma biomarker research.",

keywords = "Epigenetic biomarker, Melanoma, Metabolomics, Proteomics, Serum biomarker, mir-RNA",

author = "Douglas Donnelly and Aung, {Phyu P.} and George Jour",

year = "2019",

month = dec,

doi = "10.1016/j.semcancer.2019.06.014",

language = "English (US)",

volume = "59",

pages = "165--174",

journal = "Seminars in cancer biology",

issn = "1044-579X",

publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - The “-OMICS” facet of melanoma

T2 - Heterogeneity of genomic, proteomic and metabolomic biomarkers

AU - Donnelly, Douglas

AU - Aung, Phyu P.

AU - Jour, George

PY - 2019/12

Y1 - 2019/12

N2 - In the recent decade, cutting edge molecular and proteomic analysis platforms revolutionized biomarkers discovery in cancers. Melanoma is the prototype with over 51,100 biomarkers discovered and investigated thus far. These biomarkers include tissue based tumor cell and tumor microenvironment biomarkers and circulating biomarkers including tumor DNA (cf-DNA), mir-RNA, proteins and metabolites. These biomarkers provide invaluable information for diagnosis, prognosis and play an important role in prediction of treatment response. In this review, we summarize the most recent discoveries in each of these biomarker categories. We will discuss the challenges in their implementation and standardization and conclude with some perspectives in melanoma biomarker research.

AB - In the recent decade, cutting edge molecular and proteomic analysis platforms revolutionized biomarkers discovery in cancers. Melanoma is the prototype with over 51,100 biomarkers discovered and investigated thus far. These biomarkers include tissue based tumor cell and tumor microenvironment biomarkers and circulating biomarkers including tumor DNA (cf-DNA), mir-RNA, proteins and metabolites. These biomarkers provide invaluable information for diagnosis, prognosis and play an important role in prediction of treatment response. In this review, we summarize the most recent discoveries in each of these biomarker categories. We will discuss the challenges in their implementation and standardization and conclude with some perspectives in melanoma biomarker research.

KW - Epigenetic biomarker

KW - Melanoma

KW - Metabolomics

KW - Proteomics

KW - Serum biomarker

KW - mir-RNA

UR - http://www.scopus.com/inward/record.url?scp=85068502958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068502958&partnerID=8YFLogxK

U2 - 10.1016/j.semcancer.2019.06.014

DO - 10.1016/j.semcancer.2019.06.014

M3 - Review article

C2 - 31295564

AN - SCOPUS:85068502958

SN - 1044-579X

VL - 59

SP - 165

EP - 174

JO - Seminars in cancer biology

JF - Seminars in cancer biology

ER -

The “-OMICS” facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this